ATE146079T1 - Verwendung von antagonisten des plättchen- aktivierenden faktors bei pruritus - Google Patents

Verwendung von antagonisten des plättchen- aktivierenden faktors bei pruritus

Info

Publication number
ATE146079T1
ATE146079T1 AT91907987T AT91907987T ATE146079T1 AT E146079 T1 ATE146079 T1 AT E146079T1 AT 91907987 T AT91907987 T AT 91907987T AT 91907987 T AT91907987 T AT 91907987T AT E146079 T1 ATE146079 T1 AT E146079T1
Authority
AT
Austria
Prior art keywords
pruritus
paf
platele
activating factor
factor antagonists
Prior art date
Application number
AT91907987T
Other languages
English (en)
Inventor
David Frederick Woodward
Linda Sue Williams
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24114767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE146079(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE146079T1 publication Critical patent/ATE146079T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT91907987T 1990-05-31 1991-03-25 Verwendung von antagonisten des plättchen- aktivierenden faktors bei pruritus ATE146079T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53073990A 1990-05-31 1990-05-31

Publications (1)

Publication Number Publication Date
ATE146079T1 true ATE146079T1 (de) 1996-12-15

Family

ID=24114767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907987T ATE146079T1 (de) 1990-05-31 1991-03-25 Verwendung von antagonisten des plättchen- aktivierenden faktors bei pruritus

Country Status (9)

Country Link
EP (1) EP0532512B1 (de)
JP (1) JP3142559B2 (de)
AT (1) ATE146079T1 (de)
AU (1) AU7690891A (de)
CA (1) CA2083611A1 (de)
DE (1) DE69123580T2 (de)
ES (1) ES2095316T3 (de)
IE (1) IE911848A1 (de)
WO (1) WO1991018608A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277846B1 (en) * 1990-05-31 2001-08-21 Allergan Sales, Inc. Use of platelet activating factor antagonists as anti-pruritic agents
CA2131787A1 (en) * 1992-03-12 1993-09-16 Masahiko Shikano Antipruritic
JP3060287B2 (ja) * 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
US5854279A (en) * 1996-06-04 1998-12-29 Eisai Co., Ltd Therapeutic agent for dermatosis
FR2767692B1 (fr) * 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
CN110339191B (zh) * 2018-04-08 2022-08-02 成都百裕制药股份有限公司 银杏萜内酯在制备预防和/或治疗真性红细胞增多症的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8418424D0 (en) * 1984-07-19 1984-08-22 Scras Inhibition of platelets aggregation
DE3502392A1 (de) * 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
PT81492B (pt) 1985-09-17 1988-03-03 Ciba Geigy Ag Processo para a preparacao de novos eteres de resorcina fluorados

Also Published As

Publication number Publication date
CA2083611A1 (en) 1991-12-01
JP3142559B2 (ja) 2001-03-07
DE69123580D1 (de) 1997-01-23
EP0532512B1 (de) 1996-12-11
EP0532512A4 (en) 1993-05-05
JPH05507467A (ja) 1993-10-28
EP0532512A1 (de) 1993-03-24
IE911848A1 (en) 1991-12-04
AU7690891A (en) 1991-12-31
ES2095316T3 (es) 1997-02-16
DE69123580T2 (de) 1997-06-12
WO1991018608A1 (en) 1991-12-12

Similar Documents

Publication Publication Date Title
DE3582255D1 (de) Tabakzusammensetzungen und anordnung zum ausloesen und verabreichen von gasformig nikotins.
DK0706373T3 (da) Liposomindkapslet taxol og en fremgangsmåde til anvendelse heraf
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
MX9605442A (es) Nuevos usos para antagonistas del factor de liberacion de corticotropina.
ATE100320T1 (de) Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
EP0664703A4 (de) Verfahren zum bekämpfen der pneumocystis cariuii pneumonie und dafür verwendbare verbindungen.
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
FI902846A7 (fi) Uusia 2,5-diaryyli-tetrahydrofuraaneja ja niiden analogeja PAF-antagonisteina
ATE146079T1 (de) Verwendung von antagonisten des plättchen- aktivierenden faktors bei pruritus
IT1223990B (it) Procedimento per la riduzione mediante combustione dell'ossido di zolfo e dell'ossido di azoto nei combustibili ad elevato tenore di zolfo
FI952458L (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina
DE69629023D1 (de) Piperazino-derivative als neurokininantagonisten
ATE88084T1 (de) Verwendung eines gemisches zur behandlung der alopezie.
EE9800315A (et) Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
DE68912376D1 (de) Analoge von Bradykinin, dessen Synthese und dessen Benutzung in der Therapie.
DE69125175D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen
NO874596L (no) Maskin for tvinning av poelser i naturtarm.
DE69232852D1 (de) Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
IT1203713B (it) Procedimento per la realizzazione di pannelli per l'ottenimento di mobili e simili,nonche' macchina automatica per la sua attuazione
FI944606A0 (fi) Menetelmä 4-pyridyyli- ja 4-piperidinyyli-imidatsolien valmistamiseksi, jotka ovat käyttökelpoisia histamiinireseptoriantagonistien synteesin välituotteina
GB2088874B (en) Substituted quinazolones for the treatment of hypertension and bradycardia and as cardiotonic agents
FI922124A7 (fi) Atsabisykloamideja ja estereitä 5-HT3-reseptorin antagonisteina
DE3875065D1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
IT8467183A1 (it) Composizione farmaceutica per la profilassi ed il trattamento dell'arteriosclerosi.